We have studied the early stages of calcium oxalate monohydrate (COM) crystallization, mainly heterogeneous nucleation, on fixed particles. Experiments were performed using a flow system that closely simulates the human renal conditions related to COM heterogeneous nucleation. The effects of citrate, phytate, aescin and glycyrrhinic acid in the COM heterogeneous nucleation on different solid surfaces as calcium phosphate, a mixture of mucin and calcium phosphate and wax were studied. The presence of citrate at normal urinary concentrations (1.85 · 10-3M) totally inhibited the development of COM crystals only on the most hydrophobic assayed material (wax). Saponins (aescin and glycyrrhinic acid) only exhibited important inhibitory effects of COM crystallization on the hydrophobic wax substrate but in no case the formation of COM crystals was totally prevented. Phytate exerted the most remarkable effects on the heterogeneous nucleation of COM crystals, thus, when it was present at 1.43 · 10-7M, it totally prevented the development of COM crystals on the three assayed solid substrates.

Keywords:
Calcium oxalate crystallization, Heterogeneous nucleation, Inhibitors, Citrate, Phytate, Saponins
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.